Hello, Well, it’s certainly been a week. Between drug price hearings and disgruntled Bristol-Myers Squibb investors, I’m sure a lot of folks in the industry are looking forward to the week winding down. But before it does, I wanted to share some of the stories that preoccupied the healthcare team […]
Opposition to pharmaceutical company Bristol-Myers Squibb’s $US74 billion acquisition of Celgene is growing, and could endanger the deal. The acquisition is facing pushback from Bristol-Myers’ second-largest shareholder, the investment firm Wellington Management, and from activist investor Starboard Value. This level of uncertainty for such a large deal is “somewhat unprecedented” […]
Bristol-Myers Squibb Co.’s $US74 billion takeover of Celgene is in jeopardy after Bristol-Myers’ second-largest shareholder turned against it. Wellington Management, which owns a 7.7% stake in Bristol-Myers, laid out three reasons it opposed the deal. The deal was questioned by investors and analysts since it was announced. Watch Bristol-Myers Squibb […]
The annual J.P. Morgan Healthcare Conference kicks off on January 7 in San Francisco. The event is the start to an already-busy year for biotech, pharma, and healthcare executives. From Amazon’s healthcare ambitions, to who will pull off the next mega-merger, here’s what we expect to hear a lot about […]
Hello, and Happy New Year! Hope you all had a restful end to 2018, because 2019’s here and it’s hitting the ground running. I guess I should have known that the week before a major healthcare conference would not necessarily be a slow week for news, even with a holiday […]
Bristol-Myers Squibb has agreed to acquire Celgene, the drugmakers announced Thursday in a deal valued at $US74 billion. The deal will pay Celgene shareholders one BMS share and $US50 cash for each Celgene share they own. The deal combines a massive pharmaceutical company with a biotech giant, both of which […]
Celularity is a New Jersey-based startup co-founded by X-Prize founder Dr. Peter Diamandis and ex-Celgene executive Dr. Bob Hariri. It has raised $US250 million in funding for its stem-cell-based platform. The company is specifically using and storing placental stem cells for its regenerative medicine and cell therapy programs. The goal, […]
Biotech giant Celgene is acquiring Juno Therapeutics for $US9 billion. Juno is known for its experimental, highly personalised cancer treatments called CAR T-cell therapy, which harnesses the body’s immune system to go after certain blood cancers. It’s part of a new field of cancer therapies that . In 2017, the […]
Celgene is acquiring Juno Therapeutics, a company developing personalised cancer treatments, in a deal worth $US9 billion. It’s the second deal in 2018 for the biotech giant, which has been under pressure from investors. The highly personalised treatments Juno makes, called CAR T-cell therapy, are at the beginning of an […]
Biotech giant Celgene is in talks to acquire Juno Therapeutics, The Wall Street Journal reported on Tuesday. If the deal goes through, it’d be the second deal in the past few months for companies working on treatments that use the body’s immune cells to fight cancer, following Gilead’s acquisition of […]
Shares of Juno Therapeutics are up more than 50% in early trading on Wednesday following a Wall Street Journal report Tuesday evening that biotech giant Celgene is in talks to buy the cancer drugmaker. Juno is developing a highly personalised cancer treatment called CAR T-cell therapy (CAR is short for […]
Celgene is in talks to acquire Juno Therapeutics,The Wall Street Journal reported on Tuesday. If the deal materialises, it’d be the second in 2018 for the biotech giant, which has been under pressure from investors. Juno is known for its experimental treatments that harness the body’s immune system to treat […]
Celgene turned in a brutal third-quarter...
One biotech startup is hitting 2017 with a...
Biotech company Celgene is making another major...